Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Clin Cancer Res. 2019 Dec 18;26(6):1309–1317. doi: 10.1158/1078-0432.CCR-19-2829

Figure 2: Cluster 4 samples are subdivided into those with minimal disease burden and those without.

Figure 2:

1,242 genes from the GO pathway of neuronal systems processes distinguishes Cluster 4 patients with some metastatic disease burden (Cluster 4A) from those without (Cluster 4B). The sensitivity and specificity for identifying patients who subsequently relapsed was 65% (95% CI: 40.8–84.6%) and 75.6% (95% CI: 59.7–87.3%), respectively.